Scott E. Strome,Dan H. Schulze,David S. Block,Henrik Olsen
申请号：
US15483873
公开号：
US09926362B2
申请日:
2017.04.10
申请国别(地区):
US
年份:
2018
代理人:
摘要：
IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.
